FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma February 4, 2019 Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 EMA Recommends Granting a Marketing Authorisation for Asciminib July 8, 2022 Tomorrow is National Prescription Drug Take-Back Day! April 29, 2022 Load more HOT NEWS FDA Approves Pralsetinib for RET-Altered Thyroid Cancers Two Large Studies with New Screening Tests Show Promise for Increasing... 37-Year-Old Mom Breaks American Marathon Record What Caregivers Should Know About End-of-Life Care Issues for People With...
